Medigene AG: Departure of Chief Executive Officer Dr. Selwyn Ho and appointment of Ralph Schäfer to the Executive Management Board

Planegg/Martinsried (pta021/18.07.2025/16:00 UTC+2)

Medigene AG (FWB: MDG1, General Standard) announces that Chief Executive Officer (CEO) Dr. Selwyn Ho will leave the Company upon the expiration of his regular Executive Management Board contract on July 24, 2025.

This departure is taking place in line with the end of the contractual term and is not related to the current preliminary insolvency proceedings.

Following Dr. Ho's departure, Mr. Ralph Schäfer, currently authorized signatory (Prokurist) and General Counsel of the Company, will be appointed to the Executive Management Board effective July 25, 2025. In the event of the opening of insolvency proceedings, the power of administration and disposal over the Company's assets forming part of the insolvency estate will transfer to the insolvency administrator in accordance with Section 80 of the German Insolvency Code (InsO).

In April 2025, Chief Scientific Officer (CSO) Prof. Dr. Dolores Schendel also departed from the Executive Management Board of Medigene AG in accordance with her contract.

Furthermore, Dr. Frank Mathias resigned from the Supervisory Board of Medigene AG in April 2025 for personal reasons. This resignation was independent of the preliminary insolvency proceedings.

(end)

Emitter:	Medigene AG Lochhamer Straße 11 82152 Planegg/Martinsried Germany
Contact Person:	Medigene PR/IR
Phone:	+49 89 2000 3333 01
E-Mail:	investor@medigene.com
Website:	www.medigene.de
ISIN(s):	DE000A40ESG2 (Share)
Stock Exchange(s):	Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Hannover, Munich, Stuttgart, Tradegate